Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00017550 | Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome | PHASE2 | COMPLETED | - | — | — | Sep 1, 2000 | Nov 1, 2003 | Jan 27, 2021 | 28 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| anti-thymocyte globulin | BIOLOGICAL | - |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed early myelodysplastic syndrome (MDS) with less than 10% bone marrow blasts * Refractory anemia (RA) * RA with excess blasts (RAEB) * Hypocellular myelodysplasia * Low or intermediate-1 prognostic risk * Transfusion-dependen...